Download Free Medical Why do we need Pharmacovigilance PowerPoint Presentation

Why do we need Pharmacovigilance PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Drug Regulation, which is titled "Why do we need Pharmacovigilance?", to know about the importance of pharmacovigilance.

Tags : Drug Regulation, Pharmacovigilance, importance

Published on : Jul 20, 2021 | Views : 1984 | Downloads : 7

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

ppt slide no 1 content not found
Slide 2-

Why do we need Pharmacovigilance? Samira Saleh Prof. of Pharmacology Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University Egypt 5th Global Pharmacovigilance Summit, 8-29 April 2016, Dubai, UAE
Slide 3-

Outline Theme Ensure safer drugs to the healthcare community Adverse Drug Reactions Why is detection & assessment of ADRs inadequate in clinical trials? Pharmacovigilance Why do we need pharmacovigilance ?
Slide 4-

The study of ADRs is the concern of the field of pharmacovigilance
Slide 5-

Adverse drug reactions ADR is defined as any harm associated with the use of given drugs at a normal dosage during normal use. ADRs may occur following a single dose or prolonged administration of a drug or result from the combination of two or more drugs. The meaning of ADR differs from the meaning of "side effect ", as this last expression might also imply that the effects can be beneficial.
Slide 6-

ppt slide no 6 content not found
Slide 7-

Types of ADRs Type A: Augmented pharmacologic effects (dose-dependent and predictable) Type B: Bizarre effects (dose independent & unpredictable) Type C: Chronic effects Type D: Delayed effects Type E: End-of-treatment effects Type F: Failure of therapy Type G: Genetic reactions
Slide 8-

Possible causes of ADRS Intrinsic Idiosyncrasy Mutagenicity Carcinogenicity Teratogenicity Extrinsic Adulterations, contamination Underlying medical conditions Interactions Wrong use
Slide 9-

Serious and severe Serious (FDA): when it meets one of the following criteria: Results in death Life-threatening Requires inpatient hospitalization or prolongation of hospitalization Results in disability - or permanent change, impairment, damage or disruption in the patient's body function/structure, physical activities or quality of life Results in congenital abnormalities Requires intervention to prevent permanent damage Severity: intensity of the adverse effect
Slide 10-

Economic impact of ADRs The cost to the country of ADRs may exceed the cost of the medications themselves 30-60 % of ADRs may be preventable
Slide 11-

Before drugs become available to the patients, they are subjected to rigorous clinical studies. However, some adverse drug reactions (ADRs) are often detected ONLY after marketing. Pre-clinical Research Post-marketing Surveillance in real life patients
Slide 12-

Limitations of clinical trials Number of patients is limited: ~ 5000 Narrow population: Specific age and sex Narrow indications: only those having the specific disease studied Short duration: often no longer than a few weeks
Slide 13-

Why is detection & assessment of ADRs inadequate in clinical trials? Discovering ADR depends on: Frequency of occurrence Number of patients exposed to the drug Clinical trials are usually short-term studies conducted in a few hundred patients before marketing a drug. Therefore, further investigation on ADRs must be pursued in the post-marketing phase.
Slide 14-

ppt slide no 14 content not found
Slide 15-

Pharmaco - Vigilance Pharmaco (Greek): drug Vigilance (Latin): to keep awake or alert to keep watch the process of paying close and continuous attention
Slide 16-

Definition of Pharmacovigilance PV is the science and activities dealing with the detection, assessment, understanding and prevention of adverse effects of drugs. It has been widened to include biological products, herbals, traditional and complementary medicines.
Slide 17-

Why do we need pharmacovigilance? Reason 1: Insufficient evidence of safety Animal experiments Clinical trials prior to marketing Reason 2: Dying from a disease may be inevitable, dying from a medicine is unacceptable (WHO,2005) Reason 3: ADR are expensive
Slide 18-

Aims of pharmacovigilance Identify previously unrecognized adverse effects or changes in the patterns of adverse effects Assess the risks and benefits of medicines in order to determine what action, if any, is necessary to improve their safe use Provide information to healthcare professionals and patients to optimize safe and effective use of medicines
Slide 19-

Thus, the ultimate purpose of ADR reporting and monitoring is to reduce risks associated with drug prescribing and administration Improve patient care and patient safety Communication with international institutions working in pharmacovigilance
Slide 20-

A lesson from history 1959 – 1961 thalidomide 4,000 - 10, 000 cases of phocomelia (congenital limb defects) This lead to withdrawal of the drug from the market
Slide 21-

Pharmacovigilance is gaining importance as the number of stories of drug recalls increases
Slide 22-

ppt slide no 22 content not found
Slide 23-

Examples of licensed drugs withdrawn after marketing for drug safety reasons Thalidomide (1965) Phocomelia Practolol (1975) Sclerosing peritonitis Phenformin (1982) Lactic acidosis Rofecoxib (2004) Cardiovascular effects Veralipride (2007) Anxiety, depression, movement disorders Troglitazone (Rezulin) (2000) Hepatitis Rosiglitazone (2010 ( Increased risk of MI and death from CV causes
Slide 24-

Pharmacovigilance cycle
Slide 25-

Actions taken from the PV findings include Restriction in use Changes in the specified dose of the medicine Introduction of specific warnings in the product information Changing the legal status of a medicine, e.g., from over-the-counter to prescription only Product recall: In rare cases, removal of the medicine from the market, if the risks of a medicine are found to outweigh the benefits
Slide 26-

International collaborationin the field of pharmacovigilance WHO runs the Uppsala Monitoring Centre (started in 1968, moved to Uppsala Sweden in 1978) European Union runs the European Medicines Evaluation Agency (EMEA) United States, the FDA is responsible for monitoring post-marketing studies. Egyptian PV center
Slide 27-

ppt slide no 27 content not found
Slide 28-

Growth of membership of International Drug Monitoring Programme since 1968
Slide 29-

WHO drug monitoring programme, March 2006 As for August 2011: 106 members and 33 awaiting for full membership
Slide 30-

Cumulative number of reports
Slide 31-

ppt slide no 31 content not found
Slide 32-

Establishment of the Egyptian Pharmacovigilance Center (EPVC) The Egyptian Pharmacovigilance Center (EPVC) December 2009 مركز اليقظة الدوائية المصري ديسمبر 2009 http://epvc.gov.eg Personnel training is ongoing in order achieve the highest level of competency
Slide 33-

Middle East Members Morocco 1992 Tunisia 1993 Oman 1995 Iran 1998 Egypt 2001 Jordan 2002 Sudan 2008 Saudi Arabia 2009 Iraq 2010 United Arab Emirates
Slide 34-

The First Eastern Mediterranean Region (EMR)/Arab Countries Meeting of pharmacovigilance was held in Rabat Morocco, from 22 to 26 September 2014. Drugs - Real World Outcomes (2015)
Slide 35-

HarmonizedArab PVdefinitions and terms
Slide 36-

Why is it important for countries to support their own PV programs? Citizens may have unique traditions and diets influencing reactions to medications ADRs may be associated with traditional or herbal remedies unique to each country In some cases, ADRs to certain drugs may only occur in particular ethnic groups Alternate brands of therapy may be imported or manufactured & differ in ingredients or production processes
Slide 37-

How to report?Yellow Card Scheme The Yellow Card Scheme is the UK system for collecting information on suspected ADRs. The Scheme was founded in 1964 after the thalidomide disaster.
Slide 38-

ppt slide no 38 content not found
Slide 39-

Essential information included on the yellow card Patient details Suspected drug Suspected reaction Reporter details
Slide 40-

What should be reported? All suspected reactions including minor ones All serious, unexpected, unusual ADRs Change in frequency of a given reaction All suspected drug-drug, drug-food, drug food supplements interactions ADRs associated with drug withdrawal ADRs due to medication errors ADRs due to lack of efficacy or suspected pharmaceutical defect
Slide 41-

Why is the yellow card scheme important? The scheme acts as an early warning system for the identification of previously unrecognized reactions It enables to identify risk factors, outcomes of the ADR and other factors that may affect clinical management
Slide 42-

Who can report? ► Patients, patients relatives or patients carers ► Health care professionals (physicians, dentists, pharmacists, nurses) ► Manufacturers ► Authorities
Slide 43-

Report to whom? ► Regulatory Authority ► Industry, manufacturers ► Health professionals ► Patient organizations ► General public ► Social security
Slide 44-

Cumulative reports as of April 2004
Slide 45-

Causality assessment How likely is this medication the cause of this problem in this particular patient?
Slide 46-

The Naranjo algorithm This is a questionnaire for determining the likelihood of whether an ADR is actually due to the drug rather than the result of other factors. Probability is assigned by a score (definite, probable, possible or doubtful). Naranjo CA, Busto U, Sellers EM, et al. (1981). A method for estimating the probability of adverse drug reactions Clin. Pharmacol. Ther. 30 (2): 239–45.
Slide 47-

Naranjo scoring system
Slide 48-

Factors to be considered (Questionnaire) Are there previous conclusive reports on this reaction? Did the adverse event appear after the suspected drug was given? Did the adverse reaction improve when the drug was discontinued or a specific antagonist was given? Did the adverse reaction appear when the drug was readministered? Are there alternative causes that could have caused the reaction?
Slide 49-

Questionnaire (cont) 6. Did the reaction reappear when a placebo was given? 7. Was the drug detected in any body fluid in toxic concentrations? 8. Was the reaction more severe when the dose was increased, or less severe when the dose was decreased? 9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? 10. Was the adverse event confirmed by any objective evidence?
Slide 50-

Categories of causality (Scoring) Definite ADR > 9 Probable ADR 5-8 Possible ADR 1-4 Doubtful ADR 0
Slide 51-

Take home message Pharmacovigilance is a dynamic clinical and scientific discipline ADR reporting is the cornerstone pharmacovigilance activity The majority of global information related to ADRs arises from Western countries Countries have to support their own national pharmacovigilance. Each country should support its own PV program
Slide 52-

A successfully implemented pharmacovigilance centre can minimize, prevent and improve the use of drugs by discovering ADRs at the level of general public use. Ensure Safer Drugs to the Healthcare Community
Slide 53-

Thank you for your attention